Northern Trust Corp Blueprint Medicines Corp Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Northern Trust Corp holds 543,877 shares of BPMC stock, worth $48.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

543,877

Previous 558,890 2.69%

Holding current value

$48.4 Million

Previous $53 Million 10.57%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $1.28 Million - $1.63 Million	-15,013 Reduced 2.69%	543,877 $58.6 Million
Q1 2024 May 14, 2024	SELL	$73.17 - $99.79 $1.07 Million - $1.46 Million	-14,610 Reduced 2.55%	558,890 $53 Million
Q4 2023 Feb 13, 2024	SELL	$43.96 - $92.84 $657,641 - $1.39 Million	-14,960 Reduced 2.54%	573,500 $52.9 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $129,584 - $182,358	2,763 Added 0.47%	588,460 $29.6 Million
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $340,596 - $535,672	8,071 Added 1.4%	585,697 $37 Million
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $749,451 - $986,900	19,738 Added 3.54%	577,626 $26 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $125,438 - $203,096	3,055 Added 0.55%	557,888 $24.4 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $81,335 - $126,573	-1,629 Reduced 0.29%	554,833 $36.6 Million
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $1.06 Million - $1.65 Million	-23,485 Reduced 4.05%	556,462 $28.1 Million
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $5.72 Million - $11.6 Million	-105,722 Reduced 15.42%	579,947 $37 Million
Q4 2021 Feb 08, 2022	SELL	$94.25 - $115.99 $1.88 Million - $2.31 Million	-19,903 Reduced 2.82%	685,669 $73.4 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $841,220 - $1.14 Million	-10,388 Reduced 1.45%	705,572 $72.5 Million
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $5.85 Million - $7.14 Million	70,700 Added 10.96%	715,960 $63 Million
Q1 2021 May 12, 2021	SELL	$90.71 - $108.28 $3.9 Million - $4.65 Million	-42,955 Reduced 6.24%	645,260 $62.7 Million
Q4 2020 Feb 11, 2021	SELL	$92.08 - $124.48 $1.67 Million - $2.25 Million	-18,109 Reduced 2.56%	688,215 $77.2 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $2.11 Million - $2.95 Million	-31,810 Reduced 4.31%	706,324 $65.5 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $2.33 Million - $3.24 Million	40,885 Added 5.86%	738,134 $57.6 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $2.9 Million - $4.96 Million	60,313 Added 9.47%	697,249 $40.8 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $609,378 - $754,211	-9,132 Reduced 1.41%	636,936 $51 Million
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $3.55 Million - $4.94 Million	48,702 Added 8.15%	646,068 $47.5 Million
Q2 2019 Aug 13, 2019	BUY	$73.54 - $97.8 $5.55 Million - $7.38 Million	75,470 Added 14.46%	597,366 $56.3 Million
Q1 2019 May 13, 2019	BUY	$48.7 - $86.6 $854,587 - $1.52 Million	17,548 Added 3.48%	521,896 $41.8 Million
Q4 2018 Feb 12, 2019	SELL	$45.57 - $74.26 $752,269 - $1.23 Million	-16,508 Reduced 3.17%	504,348 $27.2 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $1.23 Million - $1.64 Million	20,945 Added 4.19%	520,856 $40.7 Million
Q2 2018 Sep 18, 2018	SELL	$60.96 - $101.18 $171,114 - $284,012	-2,807 Reduced 0.56%	499,911 $31.7 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $340,339 - $564,887	5,583 Added 1.12%	502,718 $31.9 Million
Q1 2018 May 09, 2018	BUY	$73.28 - $102.95 $53,201 - $74,741	726 Added 0.15%	497,135 $45.6 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $1.84 Million - $2.58 Million	29,267 Added 6.27%	496,409 $37.4 Million
Q3 2017 Nov 13, 2017	BUY	$42.37 - $69.67 $19.8 Million - $32.5 Million	467,142	467,142 $32.5 Million

Others Institutions Holding BPMC

# of Institutions

340

Shares Held

62M

Call Options Held

987K

Put Options Held

578K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.32B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Blueprint Medicines Corp Transaction History